Literature DB >> 12880281

Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization.

Yuh-Fun Maa1, Cassandra Shu, Mahmoud Ameri, Cindy Zuleger, Jenny Che, Jorge E Osorio, Lendon G Payne, Dexiang Chen.   

Abstract

PURPOSE: To develop stable and effective aluminum salt (alum)-adsorbed vaccine powder formulations for epidermal powder immunization (EPI) via a spray freeze-drying (SFD) process.
METHODS: Powder properties were determined using particle size analysis, tap density, and scanning electron microscopy. Alum coagulation was monitored via optical microscopy and particle sedimentation. Protein analysis was determined by the BCA protein assay, SDS-PAGE, and an enzyme immunoassay. In vivo immunogenicity and skin reactogenicity were performed on hairless guinea pigs and pigs, respectively.
RESULTS: SFD of hepatitis B surface antigen (HBsAg) adsorbed to aluminum hydroxide or aluminum phosphate using an excipient combination of trehalose/mannitol/dextran produced vaccine powders of dense particles and satisfactory powder flowability and hygroscopicity. This formulation also offered excellent long-term stability to the powder and the antigen. The two most important factors influencing alum particle coagulation are the freezing rate and the concentration of aluminum in the liquid formulation for SFD. The SFD vaccines, when delivered to hairless guinea pigs by EPI or injected intramuscularly after reconstitution, were as immunogenic as the original liquid vaccine. A further study showed that EPI with SFD alum-adsorbed diphtheria-tetanus toxoid vaccine was well tolerated, whereas needle injection of the liquid formulation caused persistent granuloma.
CONCLUSIONS: Stabilization of alum-adsorbed vaccine by SFD has important implications in extending vaccination to areas lacking a cold chain for transportation and storage and may also accelerate the development of new immunization technologies such as EPI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880281     DOI: 10.1023/a:1024493719236

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

Review 1.  Biopharmaceutical powders: particle formation and formulation considerations.

Authors:  Y F Maa; S J Prestrelski
Journal:  Curr Pharm Biotechnol       Date:  2000-11       Impact factor: 2.837

2.  Interspecies and interregional analysis of the comparative histologic thickness and laser Doppler blood flow measurements at five cutaneous sites in nine species.

Authors:  N A Monteiro-Riviere; D G Bristol; T O Manning; R A Rogers; J E Riviere
Journal:  J Invest Dermatol       Date:  1990-11       Impact factor: 8.551

3.  A new animal model for contact dermatitis: the hairless guinea pig.

Authors:  H Miyauchi; T Horio
Journal:  J Dermatol       Date:  1992-03       Impact factor: 4.005

4.  Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine.

Authors:  A Sabchareon; P Chantavanich; S Pasuralertsakul; C Pojjaroen-Anant; V Prarinyanupharb; P Attanath; V Singhasivanon; W Buppodom; J Lang
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

5.  Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles.

Authors:  D Diminsky; N Moav; M Gorecki; Y Barenholz
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

6.  Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses.

Authors:  D Chen; K F Weis; Q Chu; C Erickson; R Endres; C R Lively; J Osorio; L G Payne
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Unusual cutaneous reactions following diphtheria and tetanus immunization.

Authors:  A C Pembroke; R H Marten
Journal:  Clin Exp Dermatol       Date:  1979-09       Impact factor: 3.470

8.  A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients.

Authors:  A F Charest; J McDougall; M B Goldstein
Journal:  Am J Kidney Dis       Date:  2000-11       Impact factor: 8.860

9.  Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations.

Authors:  M Vogelbruch; B Nuss; M Körner; A Kapp; P Kiehl; W Bohm
Journal:  Allergy       Date:  2000-09       Impact factor: 13.146

10.  Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.

Authors:  Yuh-Fun Maa; Lu Zhao; Lendon G Payne; Dexiang Chen
Journal:  J Pharm Sci       Date:  2003-02       Impact factor: 3.534

View more
  7 in total

1.  Formulation of a dry powder influenza vaccine for nasal delivery.

Authors:  Robert J Garmise; Kevin Mar; Timothy M Crowder; C Robin Hwang; Matthew Ferriter; Juan Huang; John A Mikszta; Vincent J Sullivan; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2017-03-08       Impact factor: 3.246

2.  Needle-Free Dermal Delivery of a Diphtheria Toxin CRM197 Mutant on Potassium-Doped Hydroxyapatite Microparticles.

Authors:  Nikolas T Weissmueller; Heiko A Schiffter; Robert C Carlisle; Christine S Rollier; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2015-03-25

3.  Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.

Authors:  Holly J Corbett; Germain J P Fernando; Xianfeng Chen; Ian H Frazer; Mark A F Kendall
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

Review 4.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

5.  Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine.

Authors:  Nikolas T Weissmueller; Leanne Marsay; Heiko A Schiffter; Robert C Carlisle; Christine S Rollier; Robert K Prud'homme; Andrew J Pollard
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

Review 6.  Developments in the formulation and delivery of spray dried vaccines.

Authors:  Gaurav Kanojia; Rimko Ten Have; Peter C Soema; Henderik Frijlink; Jean-Pierre Amorij; Gideon Kersten
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 7.  Development of thermostable vaccine adjuvants.

Authors:  Yizhi Qi; Christopher B Fox
Journal:  Expert Rev Vaccines       Date:  2021-06-26       Impact factor: 5.683

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.